Vertex Pharmaceuticals (VRTX) EBIT (2016 - 2025)
Historic EBIT for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Q3 2025 value amounting to $1.2 billion.
- Vertex Pharmaceuticals' EBIT rose 626.18% to $1.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $4.0 billion, marking a year-over-year increase of 157684.91%. This contributed to the annual value of -$232.9 million for FY2024, which is 10607.78% down from last year.
- According to the latest figures from Q3 2025, Vertex Pharmaceuticals' EBIT is $1.2 billion, which was up 626.18% from $1.2 billion recorded in Q2 2025.
- Vertex Pharmaceuticals' EBIT's 5-year high stood at $1.2 billion during Q3 2025, with a 5-year trough of -$3.5 billion in Q2 2024.
- Over the past 5 years, Vertex Pharmaceuticals' median EBIT value was $1.0 billion (recorded in 2022), while the average stood at $718.7 million.
- Its EBIT has fluctuated over the past 5 years, first surged by 301899.74% in 2022, then crashed by 44242.99% in 2024.
- Vertex Pharmaceuticals' EBIT (Quarter) stood at $877.7 million in 2021, then rose by 17.75% to $1.0 billion in 2022, then decreased by 4.35% to $988.5 million in 2023, then increased by 3.79% to $1.0 billion in 2024, then increased by 15.61% to $1.2 billion in 2025.
- Its EBIT stands at $1.2 billion for Q3 2025, versus $1.2 billion for Q2 2025 and $630.1 million for Q1 2025.